PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11561777-0	2001	Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel.	Docetaxel	87-96	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	22-27	
11561777-0	2001	Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel.	Paclitaxel	126-136	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	22-27	
11561777-2	2001	The metabolism of docetaxel to its primary metabolite, hydroxydocetaxel, is mediated by cytochrome P450 isozymes CYP3A2 and CYP3A4 in rats and humans, respectively.	Docetaxel	18-27	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	113-119	
11561777-2	2001	The metabolism of docetaxel to its primary metabolite, hydroxydocetaxel, is mediated by cytochrome P450 isozymes CYP3A2 and CYP3A4 in rats and humans, respectively.	hydroxydocetaxel	55-71	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	113-119	
11561777-4	2001	Recently, paclitaxel, a compound structurally related to docetaxel, has been shown to significantly elevate the expression of CYP3A in rat and human hepatocytes.	Paclitaxel	10-20	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	126-131	
11561777-4	2001	Recently, paclitaxel, a compound structurally related to docetaxel, has been shown to significantly elevate the expression of CYP3A in rat and human hepatocytes.	Docetaxel	57-66	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	126-131	
11561777-9	2001	RESULTS: We observed that by day 3 of drug treatment, docetaxel at concentration in the range of 2.5-10 microM increased the CYP3A enzymatic activity and the immunoreactive CYP3A levels in a concentration-dependent manner.	Docetaxel	54-63	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	125-130	
11561777-9	2001	RESULTS: We observed that by day 3 of drug treatment, docetaxel at concentration in the range of 2.5-10 microM increased the CYP3A enzymatic activity and the immunoreactive CYP3A levels in a concentration-dependent manner.	Docetaxel	54-63	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	173-178	
11561777-10	2001	At the 10 microM level, docetaxel caused a twofold increase in the CYP3A activity and a threefold increase in the immunoreactive CYP3A levels.	Docetaxel	24-33	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	67-72	
11561777-10	2001	At the 10 microM level, docetaxel caused a twofold increase in the CYP3A activity and a threefold increase in the immunoreactive CYP3A levels.	Docetaxel	24-33	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	129-134	
11561777-11	2001	However, the docetaxel-mediated CYP3A activity and enzyme level increase were significantly lower than those mediated by paclitaxel and dexamethasone.	Docetaxel	13-22	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	32-37	
11561777-13	2001	CONCLUSIONS: Taken together, our findings raise the possibility that docetaxel at clinically relevant concentrations increases CYP3A activity.	Docetaxel	69-78	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	127-132